Articles related to BREAST SURGERY

The combination of imlunestrant plus abemaciclib demonstrated significant progression-free survival benefit across all subgroups, including patients with prior CDK4/6 inhibitor use and those with visceral metastases.

In a cohort of 601 women aged ≥65 years with low-risk breast cancer treated without radiotherapy, the 10-year local recurrence rate was 5.5%, with only 0.5% breast cancer-specific mortality.

Breast cancer surgical management requires ongoing patient education to address persistent misconceptions about treatment options and outcomes.

The recent FDA approval of Lumicell’s breast cancer imaging system introduces a novel intraoperative tool that significantly enhances the precision of tumor resections, potentially reducing the need for subsequent corrective surgeries.

With expert-led sessions encompassing a broad spectrum of breast disease management, from genetic risk assessment to cutting-edge oncological treatments, the course is a great opportunity to fortify your practice and enhance patient care.

The potential removal of the DIEP flap’s unique medical billing code by CMS could pose significant barriers to this beneficial breast reconstruction option, prompting calls for its preservation to ensure continued access and patient choice. Dive in to explore the implications of this pivotal issue for breast cancer patients and the health care system.